

# The Opioid Crisis: Treating Our Nations Veterans


Joseph G. Liberto, M.D.

Associate Chief of Staff for Education  
VA Maryland Health Care System

No relevant financial relationships or conflicts of interest. No discussion of off-label use of drugs or devices.

The presentation is the personal opinion of the presenter and does not reflect the official views of the Department of Veterans Affairs or any other Federal Agency.

6 million  
Veterans use VA  
healthcare  
(about 30% of  
all Veterans)



Veterans who  
**do not use**  
VA healthcare


# OUTLINE

- **Epidemiology of Opioid Overdose, SUD and Chronic Pain**
- Pharmacology of Opioids and Treatment of Opioid Use Disorders/ Overdose
- Assessing Veterans
- VHA Initiatives to Address the Opioid Epidemic

# Overdose Deaths Involving Opioids: 3 Waves

- 1) Natural and semi-synthetic opioid deaths increased 4-fold from 1999 to 2011; Methadone rate increased 6-fold from 1999 to 2007
- 2) Heroin death rate increased over 5-fold since 2011
- 3) Synthetic opioid (excluding methadone) death rate increased more than 6-fold from 2013 to 2016

Drugs Involved in U.S. Overdose Deaths, 1999 to 2017




\* Provisional counts for 2017 are based on data available through 12/17 but are not yet finalized

# United States (2017)

- More than 47,000 Americans Died of an Opioid Overdose (~ 130 per day)
- Approximately 1.7 Million have an Opioid Use Disorder related to Opioid Pain Relievers
- Approximately 650,000 have a Opioid Use Disorder related to heroin

National  
Institute on  
Drug Abuse

# Total Number of Drug- and Alcohol-Related Intoxication Deaths by Selected Substances<sup>1</sup>, Maryland, 2007-2017.





<sup>1</sup>Since an intoxication death may involve more than one substance, counts of deaths related to specific substances do not sum to the total number of deaths.

<sup>2</sup>Includes deaths caused by benzodiazepines and related drugs with similar sedative effects.



# Opioid Overdoses as the Tip of the Iceberg





**VA Program Evaluation  
Research Center**

Women's Past Year Prevalence (%) of Substance Use Among US Veterans in the General Population National Surveys on Drug Use and Health 2002-2012 (Hoggart et al. 2016)					
	Alcohol Use Disorder	Daily Cigarette Use	Prescription Drug Misuse	Drug Use Disorder	Substance Use Disorder
18-25 Veterans	11.5	<b>26.3</b>	14.1	5.4	14.7
18-25 Civilians	12.6	<b>15.7</b>	13.3	5.9	15.8
26-34 Veterans	6.7	23.2	6.9	1.2	7.6
26-34 Civilians	6.9	17	7.9	2.4	8.4
35-49- Veterans	5.3	<b>23.5</b>	6.1	2.1	6.1
35-49 Civilians	4.6	<b>17.5</b>	5.5	1.4	5.6
50+ Veterans	2.8	17.6	2.2	0.9	3.6
50+ Civilians	1.5	11.1	1.9	0.3	1.8
Age Adjusted Veterans	4.8	<b>21.0</b>	5.0	1.6	5.7
Age Adjusted Civilians	4.1	<b>14.5</b>	4.8	1.4	5.0




Men's Past Year Prevalence (%) of Substance Use Among US Veterans in the General Population  
National Surveys on Drug Use and Health 2002-2012 (Hoggart et al. 2017)

	Alcohol Use Disorder	Daily Cigarette Use	Prescription Drug Misuse	Drug Use Disorder	Substance Use Disorder
18-25 Veterans	<b>24.7</b>	<b>33.4</b>	18.3	10.2	<b>30.1</b>
18-25 Civilians	<b>20.5</b>	<b>18.0</b>	15.7	10.1	<b>25.4</b>
26-34 Veterans	15.3	<b>27.3</b>	9.7	4.9	17.8
26-34 Civilians	15.5	<b>20.8</b>	10.1	5.3	18.3
35-49- Veterans	10.8	<b>25.7</b>	6.0	3.3	12.6
35-49 Civilians	9.9	<b>18.4</b>	5.9	2.7	11.5
50 – 65 Veterans	6.7	<b>20.7</b>	2.7	1.3	7.5
50 – 65 Civilians	6.2	<b>15.8</b>	3.2	1.2	6.9
65+ Veterans	2.8	7.2	0.6	0.1	2.9
65+ Civilians	2.4	8.3	1.2	0.2	2.6
Age Adjusted Veterans	6.6	<b>16.5</b>	3.0	1.5	7.4
Age Adjusted Civilians	6.0	<b>13.5</b>	3.4	1.4	6.8

# Risk Factors for Overdose and OUD

## Risk factors are related to:

- Opioid prescribing
- Interaction with other medication/drugs
- Medical comorbidities
- Mental health comorbidities




Prescribing

Patient factors

**“Opioid dosage** was the factor most consistently analyzed and also associated with increased risk of overdose. Other risk factors include **concurrent use of sedative hypnotics**, use of **extended-release/long-acting opioids**, and the presence of **substance use and other mental health disorder comorbidities.**”


# Veterans: Risk Factors for Overdose/Suicide



STORM Analysis: Oliva et. al. Psych. Services 2017

## Veterans with Service-Related PTSD

■ Vietnam (Initial est.) ■ Gulf War ■ Iraq/Afghanistan (est. thru 2009)



source: US Dept of Veterans Affairs

**Current prevalence**

**General Adults in US – 1.8% m, 5.2% w**

**Vietnam - 15.2% m 8.1% w**

**Gulf War – 12.1%**


**OEF/ OIF – 13.8%**

**VA**



**U.S. Department of Veterans Affairs**  
Veterans Health Administration  
VA Maryland Health Care System

# Traumatic Brain Injury






# Medical Comorbidity - Prevalence of Pain in Veterans (US population)

**Chronic pain is more common in Veterans than in non-veterans and more often severe.**

- 66% of Veterans vs. 56% of non-veterans with pain in prior 3 month
- Severe pain in Veterans is 40% more common than in non-Veterans
- Most common pain conditions: musculoskeletal pain (joint 44%, back 33%, neck 1%)

## Severe Pain

*Pain which occurs "most days" or "every day" and bothers the individual "a lot,"*






# The Pain Challenge in VHA

**Chronic pain in Veterans receiving care in VHA is often severe and in the context of mental health comorbidities.**

- 60% of Veterans from Middle East conflicts with chronic pain, up to 75% in women Veterans.
- More than 2 Mil Veterans with chronic pain diagnosis (In 2012, 1/3 on opioids).



- **MH and Pain conditions increased in prevalence from 2008 to 2015.**
- Increase in pain scores/pain severity.


**Pain in Veterans (in VHA):**  
**1 in 3 with chronic pain diagnosis**  
**1 in 5 with persistent pain**  
**1 in 10 with severe persistent pain**

# United States (2017)

- ~ 25% of patients prescribed opioids for chronic pain misuse them
- ~ 10% of those that misuse prescribed opioids develop an Opioid Use Disorder
- ~ 5% who misuse prescribed opioids transition to heroin

National  
Institute on  
Drug Abuse

# FY2013 Overdose/Suicide Mortality - VHA



- Almost 4 out of every 5 patients who died from overdose/suicide were prescribed doses < 90 MEDD
- Almost 3 out of every 4 overdose/suicide deaths were among patients with MH/SUD diagnoses
- More than 1 out of every 2 deaths were among patients with MH/SUD diagnoses prescribed < 90 MEDD

# OUTLINE

- Epidemiology of Opioid Overdose, SUD and Chronic Pain
- **Pharmacology of Opioids and Treatment of Opioid Use Disorders/ Overdose**
- Assessing Veterans
- VHA Initiatives to Address the Opioid Epidemic

# Common Opioids

## Schedule II

**Oxycodone**

**Hydrocodone**

**Fentanyl**

**Carfentanyl**

**Meperidine**

**Morphine**

**Methadone**

**Percodan<sup>®</sup>, Tylox<sup>®</sup>, Roxicet<sup>®</sup>, OxyContin<sup>®</sup>**

**Norco<sup>®</sup>, Vicodin<sup>®</sup>, Lortab<sup>®</sup>, Lorcet<sup>®</sup>**

**Duragesic<sup>®</sup>, Actiq<sup>®</sup>**

**Wildnil<sup>®</sup>**

**Demerol<sup>®</sup>**

**MS Contin<sup>®</sup>, Oramorph<sup>®</sup>**

**Dolophine<sup>®</sup>**

## Schedule III

**Codeine**

**Buprenorphine**

**Tylenol<sup>®</sup> #3, #4**

**APAP/Codeine #2,#3,#4**

**Suboxone<sup>®</sup>, Zubsolv<sup>®</sup>, Butrans<sup>®</sup>, Bunavail<sup>®</sup>, Suboxone<sup>®</sup>,  
Sublocade<sup>®</sup>, Cizdol<sup>®</sup>**

# HEROIN, FENTANYL, CARFENTANYL (Schedule I)



Kensington  
Police Service

VA




U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System



# Opioid Receptor Types

- Delta (DOP)
- Kappa (KOP)
- **Mu (MOP)**
- Nociceptin (NOP)



# Opioid Drug Effects

## Acute Use Effects:

Euphoria	Vomiting	Constricted Pupils	Depressed Respiration
Drowsiness	Decreased Pain Sensation	Decreased Awareness	Decreased Consciousness

## Chronic Use Effects:

Physical dependence	Psychological dependence	Lethargy	Constipation
---------------------	--------------------------	----------	--------------

## Large Dose Effects:

Non-Responsive	Pinpoint Pupils	If Severe Anoxia Pupils May Dilate	Bradycardia & Hypotension
Skin Cyanotic	Skeletal Muscle Flaccid	Pulmonary edema in ~50%	Slow or Absent Respiration

CSAT


# WHY PEOPLE USE DRUGS & ALCOHOL

- It feels good
- To fit in
- To feel different
- To experiment
- To relieve boredom
- As a “social lubricant”
- To enhance performance
- To relieve pain
- To “self medicate”



Welsh

# Reward/Reinforcement



- Reward/Reinforcement is in part controlled by mu receptors in the:
  - Ventral Tegmental Area (VTA) and
  - Nucleus Accumbens with projections to
  - Prefrontal Cortex

NIDA

**ADDICTION  
IS  
TREATABLE!!!**



# TRADITIONAL VIEW OF TREATMENT OUTCOMES



**“Before”**

**Using  
“Dirty”  
Criminal**

**“After”**

**Not Using  
“Clean”  
Recovered**



Welsh

# MORE REASONABLE VIEW OF TREATMENT

**Excess Negative  
Consequences  
With No  
Improvement In  
Function**



**No Negative  
Consequences  
With Great  
Improvement In  
Function**

**Absolute use may or may  
not correlate with this**

Welsh

# GOALS OF TREATMENT

## ➤ Individual

- Total abstinence
- Reduction in alcohol or drug consumption that will allow the person to better function in all facets of life.
- Reduction in harm from substance use

## ➤ Societal

- Reduction in crime, violence, family discord, accidents, spread of HIV and other infectious diseases associated with the use of needles, and other health complications.


# Psychotherapy

- 12 Step Facilitation
- Motivational Enhancement Therapy (MET)
- Cognitive Behavioral Therapy (CBT)

# Opioid Agonist Treatment Outcomes

- 67% of patients on methadone who entered a detoxification protocol were using heroin 6-12 months later (Milby)
- Of 105 patients who discontinued methadone treatment, 82% resumed intravenous drug use by 12 months (Ball)
- 88% used opiates 3 months after buprenorphine detoxification (Gandhi)


# Mortality Per 1000 People



Sordo, et al 2017



# Mortality Per 1000 People



Sordo, et al 2017

# Opioid Agonist Treatment Outcomes

- Decrease mortality
- Decrease acquisition of HIV infection and hepatitis
- Decrease crime
- Decrease illicit-substance use
- Improve social functioning
- Increase the rate of retention in treatment
- Increase compliance with HIV medication regimen

# MEDICATIONS TO TREAT OPIOID ADDICTION

- **FDA Approved**
  - **Methadone (Methadose; Dolophine)**
  - **Buprenorphine (Suboxone; Suboxone Film; Subutex; Bunavail; Zubsolv; Sublocade)**
  - **Naltrexone (Trexan; Vivitrol)**
  - **levo-alpha-acetylmethadol (ORLAAM)**

# Function at Receptors: Full Opioid Agonists

**Mu  
receptor**

**Full agonist binding ...**

- ① fully activates the mu receptor
- ② is highly reinforcing
- ③ is the most abused opioid receptor type
- ④ substances include heroin, oxycodone, codeine, etc

Center for  
Substance  
Abuse  
Treatment

VA



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System

# Opioid Drug Effects

## Acute Use Effects:

Euphoria	Vomiting	Constricted Pupils	Depressed Respiration
Drowsiness	Decreased Pain Sensation	Decreased Awareness	Decreased Consciousness

## Chronic Use Effects:

Physical dependence	Psychological dependence	Lethargy	Constipation
---------------------	--------------------------	----------	--------------

## Large Dose Effects:

Non-Responsive	Pinpoint Pupils	If Severe Anoxia Pupils May Dilate	Bradycardia & Hypotension
Skin Cyanotic	Skeletal Muscle Flaccid	Pulmonary edema in ~50%	Slow or Absent Respiration

Center for  
Substance Abuse  
Treatment

# Function at Receptors: Partial Agonists

**Mu  
receptor**

**Partial agonist binding ...**

- ① less activation at the receptor site
- ② is relatively less reinforcing
- ③ is a less abused opioid type
- ④ includes buprenorphine

Center for  
Substance  
Abuse  
Treatment

**VA**



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System

# Function at Receptors: Opioid Antagonists

**Mu  
receptor**

**Antagonist binding ...**

- ① occupies without activating
- ② is not reinforcing
- ③ blocks agonist opioid receptors
- ④ includes naloxone (IV, SC, IM) and naltrexone (PO)

Center for  
Substance  
Abuse  
Treatment


**VA**



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System



# Partial Agonist: Ceiling Effect



Center for  
Substance  
Abuse  
Treatment

VA



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System

# OUTLINE

- Epidemiology of Opioid Overdose, SUD and Chronic Pain
- Pharmacology of Opioids and Treatment of Opioid Use Disorders/Overdose
- **Assessing Veterans**
- VHA Initiatives to Address the Opioid Epidemic

# History taking

- Family and Social history
  - What was it like growing up, abuse, parental occupations, sibling distribution, education, employment, relationships, off-spring, legal history.
- Substance History
  - Ask about each substance, manor of use, length of use, current use, highest use, longest time without using, date last used, medical complications of use, History of DTs, Seizures, past treatments
- Military History
  - ??

Reading

# Military History: General Questions

- Military History
  - Would it be ok if I talked with you about your military experience?
    - When and Where did you serve and in what branch?
    - What type of work did you do while in the service?
    - Did you have any illnesses or injuries while in the service?
    - If yes, “Can you tell me more about that”

VA Office of  
Academic  
Affiliations

# World War II Era (1939-1945)

**16 million served: ~ 500,000 surviving Veterans**

**Noise Exposure**

**Ionizing Radiation**

**Occupational (job-related) Hazards**

**Extreme Cold Injury**

**Mustard Gas**

Veterans Benefits  
Administration

# Korean War Era (1950-1953)

5.7 million served: ~ 2.25 million surviving Veterans

**Extreme Cold Injury**  
**Occupational (job-related) Hazards**  
**Noise**

Veterans Benefits  
Administration

# Vietnam War (1961-1975)

8.7 million served: ~ 7.25 million surviving Veterans

**Diseases related to Agent Orange**  
**Hearing Problems Caused by Noise**  
**Occupational (job-related) Hazards**  
**Hepatitis C (Substance Abuse)**

Veterans Benefits  
Administration

# Gulf War and Iraq War Era (1990- )

~ 5.4 million surviving Veterans

---

First Gulf War

Second Gulf War

Global War on Terrorism

Operation Active Endeavour

Operation Iraqi Freedom

Operation Enduring Freedom

Operation New Dawn



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System



**Sand, Dust and Particulate**  
**Depleted Uranium**  
**Oil Well Fires**  
**Sulfur Fire**  
**Burn Pit Smoke**  
**Chemical and Biological Weapons**  
**Chemical Agent Resistant Coating Paint**  
**Chromium**  
**Pesticides**  
**Extreme Heat Related Injuries**  
**Explosions**  
**Toxic Embedded Fragments**  
**Noise**  
**Infectious Diseases**  
**Occupational (job-related) Hazards**  
**Traumatic amputations**  
**Blast Injury**  
**Traumatic Brain Injury**  
**(PTSD/MST)**

Veterans  
Benefits  
Administration



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System

# Combat Stressors

- Losing Friends
- Not Seeing Successes
- Using Deadly Force
- Being Injured
- Seeing, Smelling, Tasting Death and Destruction
- Collateral Damage
- IED Threat
- Green on Blue Violence (Friend vs. Enemy)

Buser

# OUTLINE

- Epidemiology of Opioid Overdose, SUD and Chronic Pain
- Pharmacology of Opioids and Treatment of Opioid Use Disorders/Overdose
- Assessing Veterans
- **VHA Initiatives to Address the Opioid Epidemic**

# The VA Opioid Safety Initiatives (OSI)

- **Opioid Safety Initiatives (OSI) Aims**


- Reduce over-reliance on opioid analgesics for pain management.
- Safe and effective use of opioid therapy when clinically indicated.
- Improve access to lifesaving medication assisted treatment for opioid use disorder


- **Comprehensive OSI strategy includes**

- Provider education; Academic Detailing.
- Access to non-pharmacological modalities, incl. behavioral and CIH modalities.

- **OSI Dashboard**

- Totality of opioid use visible within VA.
- Provides feedback to stakeholders at VA facilities regarding key opioid parameters.





# The VA Opioid Safety Initiatives

# Paradigm Shift in Pain Care

- ***Paradigm shift away from opioid therapy for non-end-of-life pain management.***
  - There is no completely safe opioid dose threshold below which there are no risks for adverse outcomes.
  - Even a short-term use of low dose opioids may result in addiction.
  - Realization that any initial, short-term functional benefit will likely not be sustained in most patients.
  - Prolonged use of opioids, especially in higher doses, may lead to central sensitization and increase in pain over time (*Opioid Induced Hyperalgesia*)
  - Patients on opioids may actually experience a functional decline in the long term, measured by factors like returning to employment.
- ***Paradigm shift towards multimodal and integrated team-based pain care (biopsychosocial interdisciplinary care)***

# VA/DoD Clinical Practice Guideline: Opioid Therapy (2017)


- VA/DoD CPG includes 18 recommendations, organized in 4 topic areas
  - Initiation and Continuation of Opioids

Recommendation 1:

**“We recommend against initiation of long-term opioid therapy.**

We recommend **alternatives to opioid therapy** such as self-management strategies and other non-pharmacological treatments.

When pharmacologic therapies are used, we **recommend non-opioids over opioids”.**






# VA/DoD Clinical Practice Guideline: Opioid Therapy (2017)

- Initiation and Continuation of Opioids (cont'd)

- Recommendation against opioid therapy in patients **< 30 years of age**, in patients with active substance use disorder, and in combination with benzos.


- Risk Mitigation

- Recommendation for risk mitigation strategies, including **Informed Consent, UDT, PDMP, Overdose education and Naloxone prescribing.**
- Assess for **Suicide risk**
- Evaluate benefits and risks **at least every 3 months.**





# VA/DoD Clinical Practice Guideline: Opioid Therapy (2017)




- Type, Dose, Follow-up, and Taper of Opioids

- If prescribing opioids: **short duration and lowest dosage.**
- **No dosage is safe;** Strong rec against of opioids to > 90 MEDD.
- **Avoid long-acting opioids for acute pain, as prn, or upon initiation** of opioid therapy.
- Opioid dosage **reduction should be individualized** to patient.  
*Avoid sudden reductions; taper slowly if opioid risk > benefit,*
- For **OUD**, offer medication assisted treatment (MAT).

- Opioid Therapy for Acute Pain

- **Acute pain:** use alternatives to opioids; use multimodal pain care, **if opioids prescribe for  $\leq 3$ -5 days.**




## Pain Management - Beyond Opioids ...

# Non-Pharmacological Pain Treatments in VHA

## VA State of the Art Conference Nov. 2016: Evidence-based non-pharmacological approaches for MSK pain management

- Evidence to support CIH and conventional therapies.
- Provision of multi-modal therapies accessible from Primary Care.



## VHA Directive 1137: Advancing Complementary and Integrative Health (May 2017)

- List 1: Approaches with published evidence of promising or potential benefit.
  - Acupuncture
  - Massage Therapy
  - Tai Chi
  - Meditation
  - Yoga
  - Clinical Hypnosis
  - Biofeedback
  - Guided Imagery
- **Chiropractic Care** approved as a covered benefit in VHA in 2004 and is part of VA whole health care.
- To be made available across the system, if recommended by the Veteran's health care team.

# Stepped Care Model for Pain Management

## Stepped Care Model for Pain Management (SCM-PM)

Foundational Step: Self-Care/Self-Management


- Broad approach.

Primary Care (PACT) = Medical Home

- Coordinated care and a long-term healing relationship, instead of episodic care based on illness
- Primary Care Mental Health Integration (PCMHI) at all facilities

CARA Legislation:

- Full implementation of the SCM-PM
- Pain Management Teams at all facilities



# Stepped Care for Opioid Use Train the Trainer (SCOUTT)

- Aims to improve access to lifesaving medication assisted treatment for opioid use disorder by bringing appropriate evidence-based medication, monitoring, and brief counseling to the points of care where patients with opioid use disorder are most likely to be seen.
- These settings include Pain Management clinics, Primary Care, and Mental Health Clinics.
- In a stepped care model, care for stabilized and less complex patients can be provided in these primary clinics.

# VHA Stepped Care

- Pain Management Teams must include providers with addiction expertise to allow for integrated access to OUD evaluation and treatment.
- **Medication Assisted Treatment (MAT):**
  - Buprenorphine/naloxone
  - Methadone (through Opioid Treatment Program)
  - Naltrexone (Extended-release injectable only)
- **Stepped Care for Opioid Use Disorder**
  - Training began in August 2018

## **Self-management:**

Mutual help  
groups

Skills application

## **Primary Care, Pain Clinic, Mental Health:**

Addiction-focused  
medical  
management

1) Medical  
Management (MM)

2) Collaborative Care  
(CC)

## **SUD Specialty Care:**

Outpatient


Intensive  
outpatient

OTP

Residential

# Buprenorphine in SCOUTT level one clinics

## Buprenorphine for Opioid Use Disorder\*



*\*Includes patients with a diagnosis of OUD seen in the implementation clinic. Excludes patients seen in Clinic Stop 523 and/or prescribed buprenorphine in non-implementation clinics.*

# Overdose Education and Naloxone Distribution - OEND

- **Overdose Education (OE)**
  - How to *prevent, recognize, and respond* to an opioid overdose.
- **Naloxone Distribution (ND)**
  - FDA approved as **naloxone auto injector and nasal spray**.
  - *Dispense and train* patient and caregiver/family.
- **Target patient populations: OUD and prescribed opioids.**
- **Naloxone to be offered widely, low threshold for prescribing.**
  - Factors that increase risk for opioid overdose include h/o overdose, h/o SUD, higher opioid dosages ( $\geq 50$  MMED), or concurrent benzodiazepine use. Offer to patients with recent opioid discontinuations or during tapering of opioids
- **No cost to Veterans.**
- Rapid Naloxone Initiative: first responders, AED (defibrillator) cabinets. .



<https://www.youtube.com/watch?v=0w-us7fQE3s>




# Provider Education: Academic Detailing



- ***In-person*** educational outreach
- Evidence-based information and tools
- Pharmacists skilled in persuasive communication
- Trusted and useful ***relationship*** with providers
- Training/provider tools
- > 28,000 outreach visits (June 30, 2018)
- Multiple campaigns, examples: Pain Management, Opioid Safety Initiative, Opioid Use Disorder (OUD), Insomnia; Psychotropic Drug Safety Initiative (PDSI), incl. benzodiazepines.

## AD Exposure and Naloxone Prescribing



# VA Academic Detailing Educational Materials

## Pain/Opioid Safety Initiative



### Marijuana: Natural = Safe, Right?

Classification: Patient Factsheet  
File Name: Marijuana Use: Patient Discussion Tool  
IB&P Number: IB 10-927; P96809



### Slowly Stopping Opioid Medications Helpful Tips to Getting Off Your Opioid Successfully

Classification: Patient Factsheet  
File Name: Pain – Patient – Slowly Stopping Opioids  
IB&P Number: IB 10-1016; P96884



### Pain New Ways to Treat a Common Problem

Classification: Patient Factsheet  
File Name: Pain – Patient – Pain Information Guide  
IB&P Number: IB 10-1017; P96885

## Opioid Use Disorder

### Provider Materials



### Opioid Use Disorder A VA Clinician's Guide to Identification and Management of Opioid Use Disorder (2016)

Classification: Provider Educational Guide  
File Name: OUD – Provider AD – Educational Guide  
IB&P Number: IB 10-933; P96813



### Opioid Use Disorder Identification and Management of Opioid Use Disorder

Classification: Provider Quick Reference Guide  
File Name: OUD – Provider AD – Quick Reference Guide  
IB&P Number: IB 10-932; P96812

### Patient Materials



### Opioids: Do You Know the Truth About Opioid Use Disorder?

Classification: Patient Brochure  
File Name: OUD – Patient AD – Direct to Consumer  
Brochure  
IB&P Number: IB 10-937; P96829

## Opioid Overdose Education and Naloxone Distribution

### Provider Materials



### VA OEND Program Quick Reference Guide

Classification: Provider Quick Reference Guide  
File Name: OEND – Provider – Quick Reference Guide\_V2  
IB&P Number: IB 10-788; P96790



### Provider DVD: VA Overdose Rescue with Naloxone

Classification: DVD  
File Name: OEND – Patient – Provider DVD: VA Overdose  
Rescue with Naloxone  
IB&P Number: IB 10-770; P96764

### Patient Materials

### Naloxone Instructions



### Naloxone Nasal Spray 4 mg Instructions – Pocket Card

Classification: Patient Brochure  
File Name: OEND – Patient – OEND Patient Brochure –  
Pocket Card  
IB&P Number: IB 10-926; P96808




### Opioid Overdose Rescue with Naloxone: Auto-Injector Kit Instructions\_V2

Classification: Patient Brochure  
File Name: OEND – Patient – Naloxone Kit Instructions –  
Auto-Injector\_V2  
IB&P Number: IB 10-780; P96782

# Opioid Therapy Risk Report – OTRR

- Tool optimized for Primary Care Aligned teams: review their panel for all patients on long-term opioids
- Multitude of factors that potentially increase risk incl. MH diagnoses


- Opioid risk mitigation parameters including last PDMP check
- Updated nightly
- Individual report includes Visual display
  - Opioid dosage
  - Pain score (severity)
- LTOT definition: opioid dispensed in the last 90 days *and* total days supply  $\geq 90$  days in the past 180 days



	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB
3	Patient Name	Patient SSN	Date Of Birth	Age	Gender	Last 30 Days Avg Morph Equiv	RIOSORD Score / Class / Prob			Last PDMP Check Date	Days Since Check	Urine Drug Test**	Entry Date National OT Consent	Signed by IMED USER	Long-Term Opioid Therapy	Active Opioid Rx	Active Benzo Rx	Last Naloxone Dispensed	Last Visit w/PCP**	Last Visit Pain Clinic**	Last Visit Mental Health**	Last Visit SUD Tx**	DEP Dx***	SMI Dx**	OMD Dx**	PTSD Dx**	SUD Dx**
4	DOE, JOHN	1	1/1/1910	55	M	46	31	2	14%	2/26/2019	63	12/7/2018	12/11/2015	✓	✓	✓		6/21/2018	3/8/2019	3/14/2019	4/24/2019		✓	✓	✓		
5	DOE, JANE	2	1/1/1920	66	F	45	22	1	3%	2/26/2019	63	3/1/2019	5/17/2016	✓	✓			3/1/2019	3/15/2019								
6	DEF, ABC	3	1/1/1930	58	M	41	38	4	34%	1/28/2019	92	4/4/2019	8/4/2017	✓	✓	✓		11/29/2016	1/18/2019		8/8/2018	4/4/2019					✓
7	JKL, GHI	4	1/1/1940	81	M	15	29	2	14%	2/26/2019	63	3/11/2019	4/22/2016	✓	✓	✓		7/6/2018	3/15/2019	8/6/2018							✓
8	PQR, MNO	5	1/1/1950	69	M	12	24	1	3%	2/8/2019	81	2/28/2019	9/25/2015	✓	✓	✓		10/22/2018	2/8/2019	4/8/2019	1/14/2019						

# Stratification Tool for Opioid Risk Mitigation – STORM

- Predicts individual risk of overdose or suicide-related health events or death in the next year
- For patients on opioids and when considering opioid therapy.
- **Identifies patients at-risk for opioid overdose-/suicide-related adverse events.**
- **Provides patient-centered opioid risk mitigation strategies, targeted at risk level.**






	What factors contribute to my patient's risk?		How to better manage my patient's risk		How can I follow-up with this patient?		
Patient Information	Relevant Diagnoses	Relevant Medications	Risk Mitigation Strategies	Non-pharmacological Pain Tx	Care Providers	Recent Appts	Upcoming Appts
<b>Risk: Suicide or Overdose (1 yr)*</b> <b>High - Active Opioid Rx</b> 6%  PRF - High Risk for Suicide: No RIOSORD: Score: 11 Risk Class: 1  Active Station(s) • (653) Roseburg HCS <a href="#">Chart Review Note</a>	PTSD Medical Lymphoma Obesity Renal Failure	PREGABALIN • Dr Zivago Sedating Medication (Consider Tapering) ZOLPIDEM • Dr Zivago CLONAZEPAM • Dr Zivago <a href="#">Opioid Prescription History</a>	PDMP <input checked="" type="checkbox"/> 3/3/2019 Psychosocial Assessment <input checked="" type="checkbox"/> 1/28/2019 Psychosocial Tx <input type="checkbox"/> Suicide Safety Plan <input checked="" type="checkbox"/> 12/23/2009 Taper/Minimize Sedative Rx <input type="checkbox"/> Timely Follow-up (90 Days) <input checked="" type="checkbox"/> 4/25/2019 Timely UDS (1 Year) <input checked="" type="checkbox"/> 12/13/2018	Occupational Therapy <input type="checkbox"/> Pain Clinic <input checked="" type="checkbox"/> 1/28/15 Physical Therapy <input type="checkbox"/> Specialty Therapy <input type="checkbox"/> Other Therapy <input type="checkbox"/>		• 1/16/2017 Primary Care/Medicine <b>OtherRecent</b> • 4/9/2017 Chemotherapy Proc. Unit-Med. <b>MH Appointment</b> • 4/25/2017 Mental Health Clinic - Ind	None  <b>OtherRecent</b> • 8/12/2016 Laboratory  <b>MH Appointment</b> • 8/1/2016 Mental Health Clinic - Ind
<b>ZZTESTPATIENT,THE HULK</b> Last Four: 2751 Age: 68 Gender: M  <b>Risk: Suicide or Overdose (1 yr)*</b> Medium - Active Opioid Rx 2%  PRF - High Risk for Suicide: No RIOSORD: Score: Unknown  Active Station(s) • (508) Atlanta, GA <a href="#">Chart Review Note</a>	Mental Health Major Depressive Disorder Other MH Disorder PTSD Medical Hypertension	Opioid TRAMADOL • Dr Zivago Pain Medications (Sedating) GABAPENTIN • Dr Zivago <a href="#">Opioid Prescription History</a>	Data-based Opioid Risk Review <input type="checkbox"/> MEDD <= 90** <input checked="" type="checkbox"/> 15 Naloxone Kit <input type="checkbox"/> PDMP <input checked="" type="checkbox"/> 3/20/2019 Psychosocial Assessment <input type="checkbox"/> Psychosocial Tx <input checked="" type="checkbox"/> 4/11/2019 Suicide Safety Plan <input checked="" type="checkbox"/> 3/3/2010 Timely Follow-up (90 Days) <input checked="" type="checkbox"/> 4/11/2019 Timely UDS (1 Year) <input type="checkbox"/>	Active Therapies <input type="checkbox"/> CIH Therapies <input type="checkbox"/> Chiropractic Care <input type="checkbox"/> Occupational Therapy <input checked="" type="checkbox"/> 2/5/16 Pain Clinic <input type="checkbox"/> Physical Therapy <input checked="" type="checkbox"/> 3/8/18 Specialty Therapy <input type="checkbox"/> Other Therapy <input type="checkbox"/>		<b>OtherRecent</b> • 3/8/2017 Pm&Rs Physician <b>Primary Care Appointment</b> • 3/20/2017 Primary Care/Medicine <b>Specialty Pain</b> None <b>MH Appointment</b> • 4/11/2017 Mental Health Clinic - Ind	<b>OtherRecent</b> • 5/9/2016 Ophthalmology <b>Primary Care Appointment</b> • 5/8/2016 Primary Care/Medicine <b>Specialty Pain</b> None <b>MH Appointment</b> • 5/1/2016 Mental Health Clinic - Ind
<b>ZZTESTPATIENT,SUPER MAN</b> Last Four: 0001 Age: 82 Gender: M  <b>Risk: Suicide or Overdose (1 yr)*</b> Low - Active Opioid Rx 0%  PRF - High Risk for Suicide: No RIOSORD: Score: Unknown  Active Station(s) • (534) Charleston, SC <a href="#">Chart Review Note</a>	Medical Sleep Apnea	Opioid TRAMADOL • Dr Zivago <a href="#">Opioid Prescription History</a>	Data-based Opioid Risk Review <input checked="" type="checkbox"/> 4/15/2019 MEDD <= 90** <input checked="" type="checkbox"/> 15 Naloxone Kit <input type="checkbox"/> PDMP <input checked="" type="checkbox"/> 4/15/2019 Psychosocial Assessment <input type="checkbox"/> Psychosocial Tx <input checked="" type="checkbox"/> 10/30/2018 Suicide Safety Plan <input type="checkbox"/> Timely Follow-up (90 Days) <input checked="" type="checkbox"/> 4/15/2019 Timely UDS (1 Year) <input type="checkbox"/>	Active Therapies <input type="checkbox"/> CIH Therapies <input type="checkbox"/> Chiropractic Care <input type="checkbox"/> Occupational Therapy <input type="checkbox"/> Pain Clinic <input type="checkbox"/> Physical Therapy <input checked="" type="checkbox"/> 9/7/17 Specialty Therapy <input type="checkbox"/> Other Therapy <input type="checkbox"/>		<b>MH Appointment</b> None  <b>Specialty Pain</b> None  <b>OtherRecent</b> • 3/22/2017 Ophthalmology	<b>MH Appointment</b> None  <b>Specialty Pain</b> None  <b>OtherRecent</b> • 3/16/2017 Ophthalmology


# Reduction in Opioid Prescribing in VHA

Decline in Prescription Opioids Attributable to Decreases in Long-Term Use: A Retrospective Study in the Veterans Health Administration 2010–2016

Hadlandsmyth et al, J Gen Intern Med 2018



# Opioid Use Disorder (OUD) Medication for VHA Treated Veterans with OUD





# Suicide Risk, Pain, and Opioids

- Co-occurring mental illness is associated with increased risk of suicidal thoughts and behaviors in opioid-dependent individuals. (Demidenko-2017, Gen Hosp Psychiatry)
- Internal VHA data show that Veterans were at increased risk of unintentional overdose or suicide death (all manner of suicide, not just overdose) within the first six months of starting or stopping prescription opioid pain medicine. (Sordo et al-2017, BMJ)

# Suicide Risk, Pain, and Opioids

- Patients with chronic pain are twice as likely as those without chronic pain to die of suicide (Tang & Crane- 2006, Psychol Med)
  - Risk increases with the intensity of pain (Ilgen et al-2010, Suicide & Life)
  - Risk increases with opioid analgesic dose (ilgen-2016, Pain)
- Patients with opioid use disorder are 13 times more likely to die of suicide than the general population (Wilcox et al-2004, Drug Alc Dep)
  - VHA-treated Veterans are ~7 times more likely to be diagnosed with OUD than the commercially insured population (Baser et al-2014, Pain Practice)

# Ways You Can Help Prevent Suicide in Veterans with Pain, Opioid Use, or Opioid Use Disorder (OUD)

- Assess for suicide risk among all Veterans with opioid use
- Assess for opioid use among Veterans at risk for suicide
- Access the Opioid Safety Initiative Toolkit ([https://www.va.gov/painmanagement/opioid\\_safety\\_initiative\\_osi.asp](https://www.va.gov/painmanagement/opioid_safety_initiative_osi.asp))
- Direct Veterans to the VHA's online opioid safety information:
  - [https://www.va.gov/painmanagement/opioid\\_safety/index.asp](https://www.va.gov/painmanagement/opioid_safety/index.asp)
- Provide additional support, treatment, and wrap around services during transition periods on and off opioid therapy for pain and medication for OUD

# Ways You Can Help (continued)

- Ensure that Veterans considered for or receiving opioid pain medication are screened for illicit substances and other prescriptions per treatment guidelines.
- Address and treat co-occurring psychiatric conditions in Veterans who have attempted suicide or are at risk for suicide.
- Encourage medication treatment for opioid use disorder which reduces the risk of suicide.
  - Treatment with buprenorphine may benefits those with depression and OUD
- Provide opioid overdose education and naloxone for overdose reversal to Veterans and their family members

# Special THANKS

- Chris Buser, LCSW-C, BCD
- Karen Drexler, MD
- Sarah Reading, MD
- Friedhelm Sandbrink, MD
- Christopher Welsh, MD
- VA Center for Medication Safety
- VA National Mental Health Program -Substance Use Disorders
- VA Pharmacy Benefits Management Services
- VA Program Evaluation Research Center
- VA Program for Pain Management
- VA Office of Academic Affiliations

# QUESTIONS ?

National Suicide Prevention Hotline  
(1-800-273-TALK)

Treatment Referral HELPLINE  
(1-800-662-HELP)



U.S. Department of Veterans Affairs  
Veterans Health Administration  
VA Maryland Health Care System

# Contact Information

Joseph G. Liberto, MD  
Associate Chief of Staff, Education  
VA Maryland Health Care System  
Joseph.Liberto@va.gov